| Description | Arazine (N-Acetyl-S-farnesyl-L-cysteine) can be a a substrate for isoprenylcysteine methyltransferase by competing with prenylated G protein or its receptors site. Arazine is a cell-permeable modulator of G protein and GPCR signaling. |
| In vitro | Arazine (10–100 μM; 8h) significantly affects the HMEC-1 cell viability as measured by trypan blue exclusion in HMEC-1 cell. Arazine (2h) inhibits ATPγS induced CXCL1, CXCL8 and CCL2 production as a dose-dependent manner in HMEC-1 cell[2]. |
| In vivo | Arazine (2,000 μg/20 μl) produces a dose-dependent inhibition of the TPA-induced edema, with the maximal reduction of edema approaching 73%, with an ED50 of 55 μg/20 μl[2]. |
| Synonyms | N-Acetyl-S-farnesyl-L-cysteine |
| molecular weight | 367.55 |
| Molecular formula | C20H33NO3S |
| CAS | 135304-07-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Adhami K, et al. N-acetyl-S-farnesyl-l-cysteine suppresses chemokine production by human dermal microvascular endothelial cells.Exp Dermatol. 2012 Sep;21(9):700-5. 2. Gordon JS, et al. Topical N-acetyl-S-farnesyl-L-cysteine inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site.J Invest Dermatol. 2008 Mar;128(3):643-54. Epub 2007 Sep 20. |